2770-9183

Cancer Innovation

Wiley (John Wiley & Sons)

View prefix report (10.1002)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 71 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact71 DOIs
2

Attach ORCID iDs across 64 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact64 DOIs
3

Deposit reference lists for 54 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact54 DOIs

DOIs for this ISSN

Showing the top 5 of 230 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Comparison of nomogram and machine‐learning methods for pred… (10.1002/cai2.24)
ORCID
32.53 19
2 Expert consensus on the clinical application of antibody‐dru… (10.1002/cai2.8)
ORCID
29.40 14
3 Integrative genomic and transcriptomic profiling of pulmonar… (10.1002/cai2.112)
ORCID
23.86 8
4 The inauguration of <i>Cancer Innovation</i> (10.1002/cai2.19)
Abstract References
23.86 2
5 Pooled analyses of randomized controlled trials on pyrotinib… (10.1002/cai2.21)
Abstract
22.58 7
6 Mesoscience in cell biology and cancer research (10.1002/cai2.33)
ORCID
22.58 7
7 High BRCA1 expression is an independent prognostic biomarker… (10.1002/cai2.65)
Abstract
22.58 7
8 Expert Consensus on the Clinical Application of PI3K/AKT/mTO… (10.1002/cai2.70008)
ORCID
21.13 6
9 Guidelines for the Diagnosis and Treatment of Advanced Breas… (10.1002/cai2.70032)
ORCID
21.13 6
10 The road toward breast cancer single‐disease quality control… (10.1002/cai2.93)
Abstract
21.13 6
11 Expert consensus on the clinical application of PI3K/AKT/mTO… (10.1002/cai2.10)
ORCID
19.45 5
12 A pan‐cancer analysis of Wnt family member 7B in human cance… (10.1002/cai2.139)
ORCID
19.45 5
13 The antiferroptotic role of TRIM7: Molecular mechanism and s… (10.1002/cai2.77)
Abstract
19.45 5
14 Clinical practice guidelines for full‐cycle standardized man… (10.1002/cai2.111)
ORCID
17.47 4
15 <sup>18</sup>F‐FDG PET/CT findings of paratesticular alveola… (10.1002/cai2.121)
ORCID
17.47 4
16 Flexible bioelectronic innovation for personalized health ma… (10.1002/cai2.61)
Abstract
17.47 4
17 Artificial Intelligence‐Based Methods: The Path Forward in A… (10.1002/cai2.70019)
Abstract
17.47 4
18 Re‐Innovation in Clinical Trial Designs Based on Precision T… (10.1002/cai2.70028)
Abstract
15.05 3
19 Retinoic acid receptor responder 2 and lipid metabolic repro… (10.1002/cai2.148)
Abstract
11.93 2
20 PD‐L1 blockade by immune checkpoint inhibitors impairs sensi… (10.1002/cai2.39)
Abstract
11.93 2
21 Ecological view of carcinogenesis: Niche‐altering (NC<sup>3<… (10.1002/cai2.54)
Abstract
7.53 1
22 Guideline for the Management Pathway and Quality Control of… (10.1002/cai2.70005)
ORCID
7.53 1
23 Issue Information (10.1002/cai2.1)
Abstract References ORCID
0.00 0
24 Advances in research on molecular markers in immune checkpoi… (10.1002/cai2.100)
0.00 7
25 Organoid co‐culture models of the tumor microenvironment pro… (10.1002/cai2.101)
0.00 41
26 A comprehensive review of 3D cancer models for drug screenin… (10.1002/cai2.102)
0.00 48
27 <i>ALKBH5</i> gene polymorphisms and risk of neuroblastoma i… (10.1002/cai2.103)
0.00 10
28 Postmastectomy radiotherapy in breast reconstruction: Curren… (10.1002/cai2.104)
0.00 3
29 Clinical significance, molecular characterization, and immun… (10.1002/cai2.105)
0.00 5
30 Accelerated partial breast irradiation: Current evidence and… (10.1002/cai2.106)
0.00 0
31 Multifaceted roles and functions of SOX30 in human cancer (10.1002/cai2.107)
0.00 3
32 Cardiovascular disease burden in patients with urological ca… (10.1002/cai2.108)
0.00 2
33 Prognostic value of cardiovascular magnetic resonance in imm… (10.1002/cai2.109)
0.00 6
34 Identification of novel somatic fusions of <i>ERG‐VEGFA, TMP… (10.1002/cai2.11)
0.00 0
35 Novel progressive deep learning algorithm for uncovering mul… (10.1002/cai2.110)
0.00 1
36 Improvement of histone deacetylase inhibitor efficacy by SN3… (10.1002/cai2.113)
0.00 3
37 Histone deacetylase 6 as a novel promising target to treat c… (10.1002/cai2.114)
0.00 9
38 Cancer treatment with biosimilar drugs: A review (10.1002/cai2.115)
0.00 5
39 Cardiovascular toxicity with CTLA‐4 inhibitors in cancer pat… (10.1002/cai2.116)
0.00 1
40 MAPK4 facilitates angiogenesis by inhibiting the ERK pathway… (10.1002/cai2.117)
0.00 3
41 Establishment of a humanized mouse model using steady‐state… (10.1002/cai2.118)
0.00 2
42 Personalized surgical recommendations and quantitative thera… (10.1002/cai2.119)
0.00 10
43 ATF4/TXNIP/REDD1/mTOR signaling mediates the antitumor activ… (10.1002/cai2.12)
0.00 6
44 Identification of a disulfidptosis‐related prognostic signat… (10.1002/cai2.120)
0.00 1
45 Identification of NR3C2 as a functional diagnostic and progn… (10.1002/cai2.122)
0.00 7
46 Synergistic effect of additional anlotinib and immunotherapy… (10.1002/cai2.123)
0.00 1
47 A lactate‐responsive gene signature predicts the prognosis a… (10.1002/cai2.124)
0.00 7
48 Identification of collagen subtypes of gastric cancer for di… (10.1002/cai2.125)
0.00 5
49 Efficacy and safety of first‐line regimens for advanced HER2… (10.1002/cai2.126)
0.00 8
50 High‐fat‐diet‐induced obesity promotes simultaneous progress… (10.1002/cai2.127)
0.00 0